Patents by Inventor Jean-François MARGATHE

Jean-François MARGATHE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF
    Publication number: 20240124452
    Abstract: The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.
    Type: Application
    Filed: November 16, 2023
    Publication date: April 18, 2024
    Inventors: Andrew BELFIELD, Clifford David Jones, Jean-François Margathe, Chiara Colletto
  • Fused bicyclic RAF inhibitors and methods for use thereof
    Patent number: 11858930
    Abstract: The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: January 2, 2024
    Assignee: JAZZ PHARMACEUTICALS IRELAND LIMITED
    Inventors: Andrew Belfield, Clifford David Jones, Jean-François Margathe, Chiara Colletto
  • CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS
    Publication number: 20220041595
    Abstract: The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitor enantiomers of formula (I), (Ia), (Ib), (II), (IIa), or (IIb), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, with high enantiomeric excess (% ee). The disclosure also relates to method of using the compound of formula (I), (Ia), (Ib), (II), (IIa), or (IIb), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.
    Type: Application
    Filed: July 28, 2021
    Publication date: February 10, 2022
    Inventors: Andrew BELFIELD, Neil HAWKINS, Steven Christopher GLOSSOP, Jean-François MARGATHE, Clifford David JONES, Chiara COLLETTO
  • FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF
    Publication number: 20220033398
    Abstract: The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.
    Type: Application
    Filed: July 28, 2021
    Publication date: February 3, 2022
    Inventors: Andrew BELFIELD, Clifford David JONES, Jean-François MARGATHE, Chiara COLLETTO